The Cannabis Collection
In 2014, the Multidisciplinary Association for Psychedelic Studies (MAPS) received approval for the first-ever trial of medical marijuana to treat PTSD in US veterans, but approval by the US Drug Enforcement Agency didn’ t occur until the spring of 2016. In the meantime, however, marijuana is already legalized for medical use in 25 US states (as of June 2016). With this increased availability comes a responsibility for the medical community to understand the existing research and to share with patients any risks associated with marijuana use.
The 2 most studied chemicals found in cannabis have been THC [delta-9-tetrahydrocannabinol], a stimulant to cannabinoid brain receptors, and cannabidiol, most likely a depressant. Still, we are uncertain about how these 2 active ingredients work in concert, don’ t know enough about the other 400+ chemicals in cannabis, and have yet to determine the pharmacodynamics of dosing and distinguish individual pharmacokinetics. The purpose of this special collection is to fill this gap in knowledge.
In this curated collection,* you’ ll find
- 3 Review articles
- 5 Reports of original research, with 1 RCT and 1 NESARC
- 1 Case report
- 2 Invited commentaries
- 1 Commentary derived from a teleconference with experts in the field
From this collection, you’ ll be able to
- Weigh the benefits and risks of cannabis use
- See how use may impact recovery in veterans with PTSD, then get an overview of the current evidence about medicinal marijuana and PTSD
- Discover if cannabis can ease depressive symptoms
- Understand the risk for conversion to schizophrenia and other psychoses associated with cannabis use in vulnerable individuals
- Find out if casual use leads to addiction, how synthetic cannabinoids compare with cannabis in patient outcome, and if a method to aid withdrawal from cannabis can be used to help your patients
- Evaluate the longitudinal risk from reviews of the most recent literature
*Articles identified as CME may no longer be available for credit; please check expiration dates.
Benefits and Risks
Cannabis and Neuropsychiatry, 1: Benefits and Risks
Chittaranjan Andrade, MD
J Clin Psychiatry 2016;77(5):e551-e554
Posttraumatic Stress Disorder
Samuel T. Wilkinson, MD; Elina Stefanovics, PhD; and Robert A. Rosenheck, MD
J Clin Psychiatry 2015;76(9):1174-1180
The Use of Medicinal Marijuana for Posttraumatic Stress Disorder: A Review of the Current Literature
Stephanie Yarnell, MD, PhD
Prim Care Companion CNS Disord 2015;17(3):doi:10.4088/PCC.15r01786
Depression
Treatment of Cannabis Use Among People With Psychotic or Depressive Disorders: A Systematic Review
Amanda L. Baker, PhD; Leanne Hides, PhD (Clin); and Dan I. Lubman, PhD
J Clin Psychiatry 2010;71(3):247-254
dx.doi.org/10.4088/JCP.09r05119gry
Schizophrenia and Psychoses
The Effect of Marijuana Use on the Risk for Schizophrenia
A. Eden Evins, MD, MPH; Alan I. Green, MD; John M. Kane, MD; and Sir Robin M. Murray, MD, DSc, FRCP, FRCPsych, FMedSci, FRS
J Clin Psychiatry 2012;73(11):1463-1468
dx.doi.org/10.4088/JCP.12012co1c
The Impact of Cannabis and Stimulant Disorders on Diagnostic Stability in Psychosis
Grant E. Sara, MM; Philip M. Burgess, PhD; Gin S. Malhi, MD; Harvey A. Whiteford, MD; and Wayne C. Hall, PhD
J Clin Psychiatry 2014;75(4):349-356
dx.doi.org/10.4088/JCP.13m08878
Gunnar Faber, MD, PhD; Henderikus G. O. M. Smid, PhD; Arthur R. Van Gool, MD, PhD; Lex Wunderink, MD, PhD; Robert J. van den Bosch, MD, PhD; and Durk Wiersma, PhD
J Clin Psychiatry 2012;73(5):632-638
dx.doi.org/10.4088/JCP.11m07069
Progression From Cannabis Use to Addiction
Jesse R. Cougle, PhD; Jahn K. Hakes, PhD; Richard J. Macatee, MS; Michael J. Zvolensky, PhD; and Jesus Chavarria, MS
J Clin Psychiatry 2016;77(4):e444-e450
dx.doi.org/10.4088/JCP.14m09469
Synthetic Cannabinoids vs Cannabis
Nadav Shalit, MD; Ran Barzilay, MD, PhD; Gal Shoval, MD; Dan Shlosberg, MD, PhD; Nofar Mor; Nofar Zweigenhaft; Abraham Weizman, MD; and Amir Krivoy, MD
J Clin Psychiatry 2016;77(8):e989-e995
dx.doi.org/10.4088/JCP.15m09938
Withdrawal
Christopher J. C. Rodgman, MD; Christopher D. Verrico, PhD; Ray B. Worthy, MD, PhD; and Erica E. Lewis, MS
Prim Care Companion CNS Disord 2014;16(4):doi:10.4088/PCC.13l01594
dx.doi.org/10.4088/PCC.13l01594
Longitudinal Risk in Psychiatric Indications
Cannabis and Neuropsychiatry, 2: The Longitudinal Risk of Psychosis as an Adverse Outcome
Chittaranjan Andrade, MD
J Clin Psychiatry 2016;77(6):e739-e742
dx.doi.org/10.4088/JCP.16f10918
A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications
Samuel T. Wilkinson, MD; Rajiv Radhakrishnan, MD; and Deepak Cyril D’ Souza, MD
J Clin Psychiatry 2016;77(8):1050-1064
dx.doi.org/10.4088/JCP.15r10036
‘ ‹’ ‹ ‘ ‹’ ‹’ ‹’ ‹’ ‹’ ‹’ ‹’ ‹’ ‹
Save
Share
Cite
